New research highlights potential cardiovascular risk of novel anti-osteoporotic drug
Research presents new evidence which strengthens the plausibility that treatment with the novel anti-osteoporotic medicine, romosozumab, may lead to excess cardiovascular complications.
Jun 24, 2020
0
57